{"status":"success","_timestamp":1.742678092028845e+09,"_runtime":15.038967,"_step":0,"study_name":"Study from Belaroussi 2023.pdf","_wandb":{"runtime":15},"extracted_data":{"results":{"immunotherapy":{"median_rw_pfs":"5.0 months","median_os":"16.4 months","one_year_survival":"60.8%"},"group_difference":"Improved OS was observed for the immunotherapy group after 3 months (HR = 0.59; 95%CI [0.42–0.83], p < 0.01)","chemotherapy":{"one_year_survival":"48.9%","median_rw_pfs":"4.0 months","median_os":"11.6 months"}},"study_name":"Study from Belaroussi 2023.pdf","file_name":"Belaroussi 2023.pdf","treatment_regimens":["chemotherapy","immunotherapy","Atezolizumab","Avelumab","Durvalumab","Ipilimumab","Nivolumab","Pembrolizumab","Tremelimumab","chemotherapy-ICI combination"],"countries":["France"],"populations":[{"stage, histology":"IV, non-squamous lung cancer","pdl1_status":"≥50%","n":133},{"stage, histology":"IV, non-squamous lung cancer","pdl1_status":"<50% or negative","n":1019},{"pdl1_status":"≥50%","n":4,"stage, histology":"IV, squamous lung cancer"},{"n":24,"stage, histology":"IV, squamous lung cancer","pdl1_status":"<50% or negative"},{"stage, histology":"IV, unknown","pdl1_status":"unknown","n":3856}]}}